Onco-Innovations CEO Thomas O’Shaughnessy Featured on Conversations That Matter to Discuss Breakthroughs in Cancer Treatment, AI Integration, and Potential Global Expansion
Rhea-AI Summary
Onco-Innovations (OTCQB:ONNVF) CEO Thomas O'Shaughnessy was featured in an exclusive interview on Conversations That Matter, discussing the company's developments in cancer treatment and AI integration. The interview highlighted:
The company's focus on developing novel treatment for colorectal cancer and solid tumors, utilizing precision medicine to enhance traditional therapies. Their proprietary technology, developed by University of Alberta Cancer Institute scientists, employs targeted inhibitors and nanotechnology to disrupt cancer cell replication while preserving healthy tissue.
The interview also covered their recent acquisition of Inka Health AI, which is developing AI tools to optimize patient identification and enhance clinical trial efficacy. The company maintains strategic partnerships with Quantify Research and AstraZeneca Canada to advance precision medicine approaches in cancer therapeutic development.
Positive
- Strategic acquisition of Inka Health AI to enhance clinical trials
- Partnerships with major players: AstraZeneca Canada and Quantify Research
- Proprietary cancer treatment technology from University of Alberta Cancer Institute
Negative
- None.
VANCOUVER, BC / ACCESS Newswire / March 2, 2025 / Onco-Innovations Limited (CSE:ONCO)(OTCQB:ONNVF)(Frankfurt: W1H)(WKN:A3EKSZ) ("Onco" or the "Company") is pleased to announce that its CEO, Thomas O'Shaughnessy, was recently featured in an exclusive interview on Conversations That Matter, a widely distributed long-form program showcasing thought leaders shaping the world. The program is featured in the Vancouver Sun and is broadcast across multiple television networks in British Columbia, Canada, including CHEK-TV, as well as on digital platforms. In this exclusive interview, O'Shaughnessy shared Onco-Innovations' efforts towards developing a novel treatment candidate for colorectal cancer and other solid tumours, as well as the Company's distinguished scientific team, its recent strategic acquisition of Inka Health AI, and the Company's progress toward advancing clinical trials.
The interview delved into Onco-Innovations' pioneering approach to research and development regarding cancer treatment, which focuses on precision medicine to enhance the effectiveness of traditional therapies such as chemotherapy and radiation. O'Shaughnessy highlighted the Company's proprietary technology, developed by leading scientists from the University of Alberta Cancer Institute, including the use of targeted inhibitors and nanotechnology to disrupt cancer cell replication while preserving healthy tissue. He also discussed how the recently-acquired Inka Health AI is developing tools to leverage artificial intelligence to optimize patient identification and enhance clinical trial efficacy. Through this acquisition, he added, Onco-Innovations will continue to focus on building partnerships with research organizations such as Quantify Research, and big-pharma, such as AstraZeneca Canada, collaborations that the Company believes will play a crucial role in advancing a precision medicine approach to cancer therapeutic development.
"Being featured on Conversations That Matter gives us an incredible opportunity to share Onco-Innovations' story and reach a broader audience. It's vital for us to communicate the novel work we're doing in precision cancer therapeutic development and how we're striving to develop innovative therapies," said Thomas O'Shaughnessy, CEO of Onco-Innovations. "We are committed to advancing our research, accelerating clinical trials, and ultimately making a global impact in the fight against cancer."
You can watch the interview online at the Conversations That Matter website, their YouTube channel, their Vimeo channel, and the Vancouver Sun website. It will also be broadcast on British Columbia based stations, CHEK-TV, CFTK-TV, CJDC-TV, and CKFR-AM. Please check the individual station websites for specific air dates and times.
About Onco-Innovations Limited
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to prevent and cure cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours, setting new standards in cancer treatment. Onco's commitment to excellence and innovation drives it to develop advanced therapies that improve patient outcomes and offer hope in the fight against cancer.
ON BEHALF OF ONCO-INNOVATIONS LIMITED,
"Thomas O'Shaughnessy"
Chief Executive Officer
For more information, please contact:
Thomas O'Shaughnessy
Chief Executive Officer
Tel: + 1 888 261 8055
investors@oncoinnovations.com
The CSE and Information Service Provider have not reviewed and do not accept responsibility for the accuracy or adequacy of this release.
Forward-Looking Statements Caution. This news release contains forward-looking statements relating to the further development, potential commercialization and benefits of the Company's research initiatives, and the prospects of the Company, including its ability to safeguard its technologies, and the Company's business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "potential", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to further develop, prove out or commercialize any of the Company's technologies, the failure to receive a patent or to otherwise safeguard the Company's intellectual property rights, the failure to successfully complete further trials and studies, and other risks detailed from time to time in the filings made by the Company with securities regulators. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
SOURCE: Onco-Innovations Limited
View the original press release on ACCESS Newswire
FAQ
What is Onco-Innovations' (ONNVF) approach to cancer treatment development?
How will the Inka Health AI acquisition benefit ONNVF's clinical trials?
Who are Onco-Innovations' (ONNVF) key strategic partners in cancer research?
What types of cancer is ONNVF targeting with their treatment candidate?
